PARP1 and cardiovascular disorder: The present study confirmed that the PARP1 inhibitor, ABT-888, inhibited the effect of high concentrations of aldosterone on the injury of cultured endothelial cells, suggesting a novel direction in the treatment of cardiovascular diseases caused by aldosterone.